Glucagonoma secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment. | Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Guidelines from the National Comprehensive Cancer Network include the following recommendations for follow-up after treatment of a pancreatic neuroendocrine tumor:<ref name="pmid23681843">{{cite journal| author=Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M et al.| title=Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. | journal=J Gen Intern Med | year= 2013 | volume= 28 | issue= 11 | pages= 1525-9 | pmid=23681843 | doi=10.1007/s11606-013-2490-5 | pmc=PMC3797362 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23681843 }} </ref> | |||
===== Three to 12 months post-resection: ===== | |||
History and physical examination, serum glucagon level, and computed tomography or magnetic resonance imaging. | |||
===== >1 year post-resection to a maximum of 10 years: ===== | |||
History and physical examination with serum glucagon level every 6 to 12 months. Imaging studies as clinically indicated. | |||
==References== | ==References== | ||
# National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. <nowiki>http://www.nccn.org/professionals/physician_gls/f_guidelines.asp</nowiki> (Accessed on February 27, 2016). | |||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 20:17, 1 August 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Glucagonoma secondary prevention |
|
Risk calculators and risk factors for Glucagonoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Secondary prevention measures of glucagonoma include routine glucagon levels and imaging at scheduled intervals after treatment.
Secondary Prevention
Guidelines from the National Comprehensive Cancer Network include the following recommendations for follow-up after treatment of a pancreatic neuroendocrine tumor:[1]
Three to 12 months post-resection:
History and physical examination, serum glucagon level, and computed tomography or magnetic resonance imaging.
>1 year post-resection to a maximum of 10 years:
History and physical examination with serum glucagon level every 6 to 12 months. Imaging studies as clinically indicated.
References
- National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
- ↑ Halvorson SA, Gilbert E, Hopkins RS, Liu H, Lopez C, Chu M; et al. (2013). "Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome". J Gen Intern Med. 28 (11): 1525–9. doi:10.1007/s11606-013-2490-5. PMC 3797362. PMID 23681843.